FMC Stock Drops 5.5% to $16.40
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy FMC?
FMC is down -5.5%, or -95c to $16.40.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FMC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FMC
Wall Street analysts forecast FMC stock price to rise
14 Analyst Rating
3 Buy
10 Hold
1 Sell
Hold
Current: 17.350
Low
13.00
Averages
19.08
High
28.00
Current: 17.350
Low
13.00
Averages
19.08
High
28.00
About FMC
FMC Corporation is a global agricultural sciences company engaged in providing farmers solutions that increase the productivity and resilience of their land. The Company’s crop protection solutions, including biologicals, crop nutrition, digital and precision agriculture, enable growers and crop advisers to address their challenges economically while protecting the environment. Its portfolio consists of three major pesticide categories: insecticides, herbicides and fungicides. The majority of its product lines consist of insecticides and herbicides, and it has a portfolio of fungicides mainly used in high-value crop segments. Its insecticides are used to control a wide spectrum of pests, while its herbicide portfolio primarily targets a large variety of difficult-to-control weeds. In addition, it is also investing in its Plant Health program, which includes biologicals, crop nutrition, and seed treatment products. Biological technologies serve as complements to its synthetic products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Old North State Fully Divests FMC Stake Amid Losses
- Complete Exit from FMC: Old North State Wealth Management sold its entire stake of 295,829 shares in FMC Corporation during Q1 2026, with an estimated transaction value of approximately $4.42 million, indicating a significant loss of confidence in FMC's future prospects.
- Significant Price Decline: As of April 16, 2026, FMC shares were priced at $17.58, reflecting a 50% drop over the past year, which starkly contrasts with the S&P 500's roughly 35% gain during the same period, highlighting the challenging market conditions faced by the company.
- Deteriorating Financials: FMC's annual revenue has declined by 18% to around $3.47 billion, resulting in a net loss of $2.24 billion primarily due to impairments and restructuring efforts, with management projecting further revenue declines for 2026 between $3.6 billion and $3.8 billion.
- Strategic Alternatives Considered: The company is exploring strategic alternatives, including a potential sale, while aiming to reduce $1 billion in debt through asset disposals, indicating proactive measures to improve its financial situation amidst ongoing challenges.
See More
Old North State Fully Liquidates FMC Shares
- Complete Liquidation: Old North State Wealth Management sold all 295,829 shares of FMC in Q1, with an estimated transaction value of $4.42 million, indicating a complete exit from the position and reflecting diminished confidence in FMC's future performance.
- Declining Asset Value: The position's value dropped by $4.10 million at quarter-end, illustrating the combined effects of trading and share price changes, suggesting a strategic exit after significant losses rather than routine portfolio rebalancing.
- Performance Decline: FMC's annual revenue fell by 18% to approximately $3.47 billion, resulting in a net loss of $2.24 billion primarily due to impairments and restructuring efforts, with management projecting further revenue declines for 2026, highlighting the company's severe challenges.
- Strategic Alternatives: FMC is considering strategic options, including a potential sale, while aiming to reduce $1 billion in debt through asset disposals, and this context of liquidation indicates Old North State's significantly reduced confidence in FMC's recovery prospects.
See More
FMC Corporation Shares Surge 16.8% Amid Acquisition Talks and Supply Crunch
- Stock Recovery: FMC Corporation's shares surged 16.8% in March, following a significant 72% decline in 2025, indicating a market shift towards optimism regarding its future, particularly amid supply constraints.
- Acquisition Talks: CEO Pierre Brondeau disclosed at the JPMorgan & Chase Industrials conference that investment banks are in discussions with 5 to 10 potential buyers about acquiring FMC, suggesting that heightened interest may mitigate further stock price declines.
- Supply Crunch Impact: The ongoing war in Iran has led to a supply crunch for agricultural chemicals, which could benefit FMC; however, analysts expect the financial impact to be minimal when earnings are reported, prompting cautious investor sentiment.
- New Product Approval: FMC's herbicide Isoflex received EU approval, which, while already approved in other regions, could enhance the company's financial outlook and strengthen its competitive position in the market.
See More
FMC Corporation Sees Increased Acquisition Interest Amid Supply Crunch
- Increased Acquisition Interest: FMC's CEO stated that between five and ten parties are interested in acquiring the company, which may boost market confidence in FMC, although shareholders are divided on a potential sale.
- Supply Crunch Impact: The war in Iran has tightened supplies in the agricultural chemicals sector, leading to a 16.8% rise in FMC's stock in March, despite a 72% decline in 2025, indicating market expectations for a potential turnaround.
- New Product Approval: FMC's new herbicide, Isoflex, received approval in the European Union, which could enhance the company's financial results and competitive position, despite prior approvals in other regions.
- High-Risk Financial Situation: With $4.1 billion in debt against a $2.2 billion market cap, FMC's financial health remains precarious, and analysts expect minimal earnings benefits from the current supply crunch, necessitating cautious investor assessment.
See More
FMC Explores Strategic Options to Unlock Shareholder Value
- Underwhelming Performance: FMC's revenue for 2025 fell by 5% year-over-year, while adjusted diluted earnings per share (EPS) dropped 14.9% to $2.96, indicating financial strain due to restructuring and potential sales of its Indian division, which may undermine investor confidence.
- Strong Acquisition Interest: Despite its poor performance, FMC has attracted acquisition interest from corporations and private equity firms, who believe the company has a product pipeline capable of driving future revenue and profit growth, reflecting market recognition of its potential value.
- Rising Stock Trend: Since announcing its intention to sell, FMC's stock price has surged by 28%, currently trading at $17.64, which is 11% above its early-year price of $16, contrasting with the S&P 500's 3.8% decline during the same period, indicating optimistic expectations for an acquisition.
- Acquisition Uncertainty: While initial acquisition interest is evident, the outcome remains uncertain due to the due diligence process, and if a deal does not materialize, the stock price could revert to pre-announcement levels, suggesting that long-term investors should be cautious in such unpredictable situations.
See More
FMC Pursues Strategic Options to Unlock Shareholder Value
- Revenue Decline: FMC's revenue dropped 5% year-over-year in 2025, indicating underperformance in the current market, which may hinder its ability to attract investors.
- Earnings Per Share Drop: The company's adjusted diluted EPS fell 14.9% to $2.96, reflecting weakened profitability that could lead to diminished investor confidence.
- Acquisition Interest: Despite recent poor performance, management noted strong acquisition interest from various buyers, suggesting potential growth opportunities, especially given the perceived strength of its product pipeline.
- Stock Price Volatility: Since announcing its intent to sell, FMC's stock has surged 28%, contrasting with a 3.8% decline in the S&P 500 during the same period, indicating market optimism about a potential acquisition, but also suggesting that if no deal occurs, the stock price may fall back significantly.
See More
Old North State Fully Divests FMC Stake Amid Losses
- Complete Exit from FMC: Old North State Wealth Management sold its entire stake of 295,829 shares in FMC Corporation during Q1 2026, with an estimated transaction value of approximately $4.42 million, indicating a significant loss of confidence in FMC's future prospects.
- Significant Price Decline: As of April 16, 2026, FMC shares were priced at $17.58, reflecting a 50% drop over the past year, which starkly contrasts with the S&P 500's roughly 35% gain during the same period, highlighting the challenging market conditions faced by the company.
- Deteriorating Financials: FMC's annual revenue has declined by 18% to around $3.47 billion, resulting in a net loss of $2.24 billion primarily due to impairments and restructuring efforts, with management projecting further revenue declines for 2026 between $3.6 billion and $3.8 billion.
- Strategic Alternatives Considered: The company is exploring strategic alternatives, including a potential sale, while aiming to reduce $1 billion in debt through asset disposals, indicating proactive measures to improve its financial situation amidst ongoing challenges.
See More
Old North State Fully Liquidates FMC Shares
- Complete Liquidation: Old North State Wealth Management sold all 295,829 shares of FMC in Q1, with an estimated transaction value of $4.42 million, indicating a complete exit from the position and reflecting diminished confidence in FMC's future performance.
- Declining Asset Value: The position's value dropped by $4.10 million at quarter-end, illustrating the combined effects of trading and share price changes, suggesting a strategic exit after significant losses rather than routine portfolio rebalancing.
- Performance Decline: FMC's annual revenue fell by 18% to approximately $3.47 billion, resulting in a net loss of $2.24 billion primarily due to impairments and restructuring efforts, with management projecting further revenue declines for 2026, highlighting the company's severe challenges.
- Strategic Alternatives: FMC is considering strategic options, including a potential sale, while aiming to reduce $1 billion in debt through asset disposals, and this context of liquidation indicates Old North State's significantly reduced confidence in FMC's recovery prospects.
See More
FMC Corporation Shares Surge 16.8% Amid Acquisition Talks and Supply Crunch
- Stock Recovery: FMC Corporation's shares surged 16.8% in March, following a significant 72% decline in 2025, indicating a market shift towards optimism regarding its future, particularly amid supply constraints.
- Acquisition Talks: CEO Pierre Brondeau disclosed at the JPMorgan & Chase Industrials conference that investment banks are in discussions with 5 to 10 potential buyers about acquiring FMC, suggesting that heightened interest may mitigate further stock price declines.
- Supply Crunch Impact: The ongoing war in Iran has led to a supply crunch for agricultural chemicals, which could benefit FMC; however, analysts expect the financial impact to be minimal when earnings are reported, prompting cautious investor sentiment.
- New Product Approval: FMC's herbicide Isoflex received EU approval, which, while already approved in other regions, could enhance the company's financial outlook and strengthen its competitive position in the market.
See More
FMC Corporation Sees Increased Acquisition Interest Amid Supply Crunch
- Increased Acquisition Interest: FMC's CEO stated that between five and ten parties are interested in acquiring the company, which may boost market confidence in FMC, although shareholders are divided on a potential sale.
- Supply Crunch Impact: The war in Iran has tightened supplies in the agricultural chemicals sector, leading to a 16.8% rise in FMC's stock in March, despite a 72% decline in 2025, indicating market expectations for a potential turnaround.
- New Product Approval: FMC's new herbicide, Isoflex, received approval in the European Union, which could enhance the company's financial results and competitive position, despite prior approvals in other regions.
- High-Risk Financial Situation: With $4.1 billion in debt against a $2.2 billion market cap, FMC's financial health remains precarious, and analysts expect minimal earnings benefits from the current supply crunch, necessitating cautious investor assessment.
See More
FMC Explores Strategic Options to Unlock Shareholder Value
- Underwhelming Performance: FMC's revenue for 2025 fell by 5% year-over-year, while adjusted diluted earnings per share (EPS) dropped 14.9% to $2.96, indicating financial strain due to restructuring and potential sales of its Indian division, which may undermine investor confidence.
- Strong Acquisition Interest: Despite its poor performance, FMC has attracted acquisition interest from corporations and private equity firms, who believe the company has a product pipeline capable of driving future revenue and profit growth, reflecting market recognition of its potential value.
- Rising Stock Trend: Since announcing its intention to sell, FMC's stock price has surged by 28%, currently trading at $17.64, which is 11% above its early-year price of $16, contrasting with the S&P 500's 3.8% decline during the same period, indicating optimistic expectations for an acquisition.
- Acquisition Uncertainty: While initial acquisition interest is evident, the outcome remains uncertain due to the due diligence process, and if a deal does not materialize, the stock price could revert to pre-announcement levels, suggesting that long-term investors should be cautious in such unpredictable situations.
See More
FMC Pursues Strategic Options to Unlock Shareholder Value
- Revenue Decline: FMC's revenue dropped 5% year-over-year in 2025, indicating underperformance in the current market, which may hinder its ability to attract investors.
- Earnings Per Share Drop: The company's adjusted diluted EPS fell 14.9% to $2.96, reflecting weakened profitability that could lead to diminished investor confidence.
- Acquisition Interest: Despite recent poor performance, management noted strong acquisition interest from various buyers, suggesting potential growth opportunities, especially given the perceived strength of its product pipeline.
- Stock Price Volatility: Since announcing its intent to sell, FMC's stock has surged 28%, contrasting with a 3.8% decline in the S&P 500 during the same period, indicating market optimism about a potential acquisition, but also suggesting that if no deal occurs, the stock price may fall back significantly.
See More
